8-K: Oramed Announces Joint Venture to Advance Oral Insulin Development

Oramed Pharmaceuticals is spinning off its oral drug delivery technology into a new joint venture, OraTech Pharmaceuticals, with Hefei Tianhui Biotech Co., Ltd. (HTIT), to accelerate the development and commercialization of oral insulin.

Summary

• Oramed Pharmaceuticals is forming a joint venture with Hefei Tianhui Biotech Co., Ltd. (HTIT) called OraTech Pharmaceuticals to focus on oral drug delivery.
• Oramed will transfer its oral insulin and Protein Oral Delivery (POD) technology to OraTech.
• Oramed shareholders will receive a majority of Oramed's equity interest in OraTech, allowing them to participate directly in its future success.
• Oramed and HTIT will contribute a combined $75 million in capital to OraTech.
• HTIT will provide a supply agreement for oral insulin capsules.
• OraTech plans to reinitiate a Phase 3 clinical trial in the U.S. with a revised protocol.
• OraTech will advance the registration of oral insulin in the U.S. and other countries.
• OraTech will receive royalty payments from sales of oral insulin in China, where a Marketing Authorization Application has been submitted.
• HTIT will provide manufacturing support to OraTech.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with the formation of a joint venture, significant investment, and plans for clinical trials and commercialization. The focus on innovation and potential to redefine diabetes care contributes to the positive sentiment.

Positives

• OraTech will have global marketing rights to Oramed's POD oral protein delivery technology.
• HTIT's state-of-the-art manufacturing capabilities will support OraTech.
• The $75 million investment will provide substantial resources to drive development, commercialization, and clinical advancement.
• OraTech will leverage HTIT's expertise in capsule production and cost-efficient manufacturing.
• OraTech is uniquely positioned to advance its programs, including the planned reinitiation of a pivotal Phase 3 clinical trial in the United States.

Risks

• The document contains forward-looking statements that are subject to risks and uncertainties.
• Satisfaction of closing conditions for the contemplated transactions is uncertain.
• The company's most recent annual and quarterly reports and other filings with the Securities and Exchange Commission contain risks and uncertainties that could cause actual results to differ materially from those contemplated in the forward-looking statements.

Future Outlook

OraTech is potentially set to redefine diabetes care and transform the future of oral biologics and chronic disease management.

Management Comments

• Nadav Kidron, Chief Executive Officer of Oramed, stated that OraTech brings together Oramed's technology and clinical development expertise with HTIT's state-of-the-art manufacturing capabilities.
• Nadav Kidron also stated that OraTech will be singularly focused on bringing oral insulin to market and unlocking the broader potential of oral drug delivery for additional therapeutic targets.

Industry Context

The announcement highlights the growing interest in oral drug delivery systems, particularly for biologics like insulin, which could significantly improve patient convenience and adherence compared to traditional injections.

Comparison to Industry Standards

• Novo Nordisk and Eli Lilly are major players in the insulin market, but primarily offer injectable products.
• Other companies are also exploring oral insulin delivery, such as Biocon and Generex Biotechnology, but Oramed's POD technology aims to offer a unique advantage in terms of drug protection and absorption.
• The joint venture structure is similar to other collaborations in the pharmaceutical industry, where companies combine expertise and resources to accelerate drug development and commercialization.

Related Party Transactions

• The document details a joint venture agreement between Oramed and HTIT, which involves related party transactions such as the transfer of assets and capital contributions.

Stakeholder Impact

• Shareholders of Oramed will receive equity in OraTech, allowing them to participate in its future success.
• Patients may benefit from the development and commercialization of oral insulin and other POD-based therapies.
• Employees of Oramed may be affected by the transfer of assets and operations to OraTech.
• The joint venture may impact competitors in the diabetes care market.

Next Steps

• Complete the spin-off of Oramed's Protein Oral Delivery (POD) technology into OraTech Pharmaceuticals Inc.
• Transfer Oramed's proprietary oral insulin and POD technology, along with other pipeline assets, into OraTech.
• Reinitiate a pivotal Phase 3 clinical trial in the United States.
• Advance registration of oral insulin in the U.S. and other countries.
• Prepare for commercialization of oral insulin in China.
• Provide further details on Oramed's plans and initiatives in a shareholder letter in the coming weeks.

Key Dates